Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-104147
Filing Date
2026-03-12
Accepted
2026-03-12 16:10:50
Documents
86
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K okur-20251231.htm   iXBRL 10-K 4043617
2 EX-4.2 okur-ex4_2.htm EX-4.2 69694
3 EX-10.18 okur-ex10_18.htm EX-10.18 74145
4 EX-23.1 okur-ex23_1.htm EX-23.1 3936
5 EX-31.1 okur-ex31_1.htm EX-31.1 20134
6 EX-31.2 okur-ex31_2.htm EX-31.2 20257
7 EX-32.1 okur-ex32_1.htm EX-32.1 18529
8 GRAPHIC img162180743_0.jpg GRAPHIC 92711
9 GRAPHIC img162180743_1.gif GRAPHIC 135185
10 GRAPHIC img162180743_2.gif GRAPHIC 28353
11 GRAPHIC img162180743_3.jpg GRAPHIC 244912
  Complete submission text file 0001193125-26-104147.txt   12444607

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT okur-20251231.xsd EX-101.SCH 1354367
89 EXTRACTED XBRL INSTANCE DOCUMENT okur-20251231_htm.xml XML 1360578
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40315 | Film No.: 26747791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)